Current strategies to prevent stroke in atrial fibrillation may require a closer look, according to two new studies.

Modern endpoint management is undergoing a transformation through automation. This webinar explores the practical journey ...

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction ...

Trodelvy did not meet the primary endpoint of progression-free survival in the ASCENT-07 trial for HR-positive, HER2-negative ...

Microchip’s LAN866x 10BASE-T1S endpoint devices use the Remote Control Protocol (RCP) to extend Ethernet connectivity in ...

Sizwe Africa IT Group, which positions itself as a leading ICT solutions provider, has formed a strategic partnership with Hexnode, a global leader in unified endpoint management (UEM), delivering ...

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...

Novartis (NVS) (OTCPK:NVSEF) has announced that its next-generation malaria treatment, KLU156 (GanLum), developed with Swiss ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

Current guidelines for the U.S. and Europe have a recommendation of class 2b, level of evidence B or C for LAAO in patients ...